Proactive Investors - Run By Investors For Investors

Emerald Health Therapeutics' joint venture receives TSX Venture Exchange conditional approval

The Vancouver-based company will invest C$5 million for a 51% equity stake in Emerald Health Naturals
handshake
Emerald Health Therapeutics will invest C$5 million for a 51% equity stake in the joint venture, known as Emerald Health Naturals

Emerald Health Therapeutics Inc (CVE:EMH, OTCMKTS:EMHTF) said Monday that it has received conditional approval from the TSX Venture Exchange for its joint venture with San Diego-based Emerald Health Bioceuticals (EHB).

Vancouver-based Emerald Health Therapeutics will invest C$5 million for a 51% equity stake in the joint venture, known as Emerald Health Naturals.

READ: Emerald Health Therapeutics files 17 US patent applications to protect product line

EHB will grant the joint venture exclusive Canadian distribution rights to its product line in exchange for 49% equity ownership. EHB’s products consist of nutritional supplements that use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system of neurotransmitters that bind to cannabinoid receptors.

Market research commissioned by Emerald Health Therapeutics has found that about 60% of legal cannabis users also use natural health products.

Shares of Emerald Health Therapeutics slipped C$0.18 to C$3.74 in Canada. They slipped US$0.16 to US$2.84 in OTC trading.


Contact Dennis Fitzgerald at [email protected]
 

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full EMH profile View Profile

Emerald Health Therapeutics Inc Timeline

Related Articles

bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use